Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

32.98 +0.29 (+0.89%)
Official Closing Price Updated: 4:10 PM EDT, Sep 25, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 19,183,195
Open 32.69
Bid (Size) 32.94 (1)
Ask (Size) 32.97 (1)
Prev. Close 32.69
Today's Range 32.41 - 32.98
52wk Range 32.50 - 54.93
Shares Outstanding 5,606,688,356
Dividend Yield 4.73%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Amazon Invests $4B In ChatGPT Competitor, Hollywood Writers Accept Tentative Deal, ChatGPT Challenges Siri And Alexa With Introduction Of Verbal Responses: Today's Top Stories
Benzinga 
Via Benzinga
CDC Backs Pfizer's RSV Infection Maternal Vaccine During Pregnancy As Protection For Infants
Friday, The Centers for Disease Control and Prevention recommended the first respiratory syncytial virus (RSV) vaccine for pregnant people to protect their newborns from severe RSV 
Via Benzinga

Performance

YTD
-35.66%
-35.66%
1 Month
-9.35%
-9.35%
3 Month
-10.60%
-10.60%
6 Month
-18.00%
-18.00%
1 Year
-24.75%
-24.75%

More News

Read More
Exploring NYSE:PFE's dividend characteristics.
Via Chartmill
Beware! 3 Healthcare Stocks Waving Massive Red Flags Right Now.
Via InvestorPlace
2 Dividend Growth Stocks to Buy Right Now
Via The Motley Fool
Why NYSE:PFE is a Top Pick for Dividend Investors.
Via Chartmill
Check Out What Whales Are Doing With PFE
Via Benzinga
Pfizer Broadens Portfolio of Respiratory Vaccines Recommended by CDC Advisory Committee with ABRYSVO™ for RSV
From Pfizer Inc.
Via Business Wire
Most Active Equity Options For Midday - Friday, Sep. 22
Via Talk Markets
Seagen Pops After Scoring A 'Must-Win' For Its $43 Billion Takeover By Pfizer
Via Investor's Business Daily
California Attorney General Cracks Down On Deceptive Abortion Pill Reversal Claims
Via Benzinga
Pfizer Stock: Bear vs. Bull
Via The Motley Fool
3 Bargain Stocks to Buy in a Market That's Priced for Perfection
Via The Motley Fool
Updated Covid Vaccine US Rollout Hit by Insurance Coverage Delays - What It Means?
Via Benzinga
Exposures COVID-19
Beware! 3 Biotech Stocks Waving Massive Red Flags Right Now
Via InvestorPlace
With New COVID-19 Boosters in Tow, Which Is the Better Buy: Pfizer, BioNtech, or Moderna Stock?
Via The Motley Fool
Exposures COVID-19
Flee to Healthcare Stocks if Recession Rears its Head?
Via MarketBeat
Topics Economy
Exposures Economy Interest Rates
Beware! 3 Nasdaq Stocks Waving Massive Red Flags Right Now.
Via InvestorPlace
3 Stocks to Avoid Like the Plague Right Now: MRNA, GPS, PTON
Via InvestorPlace
Preventable Vaccines Market May See a Big Move : AstraZeneca, GlaxoSmithKline, Merck
Via SBWire
Amazon Poaches Microsoft's Product Chief, Google And DoD Team Up For AI-Powered Microscope To Identify Cancer, Rocket Lab's 41st Mission Succumbed To Technical Issues: Today's Top Stories
Via Benzinga
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
From Pfizer Inc.
Via Business Wire
First Human Clinical Trials Of A Potentially “Game-Changing Broad Spectrum Antiviral” Are Progressing Successfully – Drug Could Treat COVID, RSV And Many Other Respiratory Viruses
Via News Direct
Exposures COVID-19
European Commission Approves GSK/Pfizer-Backed HIV Infection Prevention Drug
Via Benzinga
Cramer Says 'I Can't Tell You To Sell It Here,' As Massive Pharma Stock Falls 34% YTD
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.